MEDICURE GETS FDA/TPD APPROVALS FOR MC-1 PHASE II TRIAL.

Medicure Inc. (TSX:MPH), Winnipeg, Manitoba, a cardiovascular drug discovery and development company, has received approval from the U.S. Food and Drug Administration and the Canadian Therapeutic Product Directorate (TPD) to initiate a large Phase II clinical study to treat up to 900 patients with the company's lead drug compound, MC-1. The study, to be called MEND - CABG, will evaluate the ischemic reperfusion and neuro- protective effects of MC-1 in patients undergoing high-risk Coronary Artery Bypass Graft (CABG) surgery.

Coronary Artery Disease (CAD) is a condition